- Home
- IMUX vs BYSI Comparison
IMUX vs BYSI Comparison
Compare IMUX & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMUX | BYSI |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.2M | 58.4M |
| IPO Year | 2013 | 2016 |
Fundamental Metrics
Financial Performance| Metric | IMUX | BYSI |
|---|---|---|
| Price | $1.24 | $1.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $4.25 | N/A |
| AVG Volume (30 Days) | ★ 4.6M | 19.9K |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $0.98 |
| 52 Week High | $1.35 | $3.44 |
Technical Indicators
Market Signals| Indicator | IMUX | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 74.15 | 46.63 |
| Support Level | $0.61 | $1.38 |
| Resistance Level | N/A | $1.81 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 89.79 | 57.14 |
Price Performance
Historical ComparisonAbout IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.